2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders

European Journal of Haematology

Volumn 58, Issue 1, 1997, Pages 46-50

  Rondelli, D ^a,d   Lauria, F ^b   Zinzani, P L ^a   Raspadori, D ^a   Ventura, M A ^a   Galieni, P ^b   Birtolo, S ^b   Forconi, F ^b   Algeri, R ^c   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Hospital of Grosseto   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

2 CdA; B CLL; B NHL; clinical response; CTCL

Indexed keywords

CIPROFLOXACIN; CLADRIBINE; FLUDARABINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL;

EID: 8044250299     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01409.x     Document Type: Article

References (29)

1. FAGUET GB. Chronic lymphocytic leukemia: an updated review. J Clin Oncol 1994: 12: 1974-1990.
2. HORNING SJ, ROSENBERG SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984: 311: 1471-1475.
3. FRENCH COOPERATIVE GROUP ON CHRONIC LYMPHOCITIC LEUKEMIA. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 1990: 75: 1414-1421.
4. YOUNG RC, LONGO DL, GLATSTEIN E, et al. The treatment of indolent lymphomas: watchful waiting v. aggressive combined modality treatment. Semin Hematol 1988: 25 (Suppl. 2): 11-16.
5. MONTSERRAT E, ALCALA A, ALONSO C, et al. A randomized trial comparing chlorambucil plus prednisone vs. cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988: 30: 429-432.
6. HOPPE RT, KUSHLAN P, KAPLAN HS, et al. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981: 58: 592-598.
7. SAVEN A, PIRO LD. The newer purine analogs. Cancer 1993: 72: 3470-3480.
8. GREVER MR, SIAW MF, JACOB WF, et al. The biochemical and clinical consequences of 2-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1993: 57: 406-417.
9. DEARDEN C, CATOVSKY D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990: 62: 4-5.
10. ZINZANI PL, LAURIA F, RONDELLI D, et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Haematol 1993: 51: 93-97.
11. ZINZANI PL, LAURIA F, RONDELLI D, et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993: 4: 575-578.
12. KAWASAKI H, CARRERA CJ, PIRO LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic activity of 2-chloro deoxyadenosine. Blood 1993: 81: 597-601.
13. SETO S, CARRERA CJ, KUBOTA M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing lymphocytes. J Clin Invest 1985: 75: 377-383.
14. SAVEN A, CARRERA CJ, CARSON DA, et al. 2-chlorode-oxyadenosine treatment for refractory chronic lymphocytic leukemia. Leuk Lymph 1991 (Suppl.): 133-138.
15. JULIUSSON G, LILIEMARK J. High complete remission rate from 2-chloro-2-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1993: 11: 679-689.
16. BETTICHER DC, FEY MF, VON ROHR, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukemias. Ann Oncol 1994: 5: 57-64.
17. TALLMAN MS, HAKIMIAN D, ZANZIG C, et al. Cladribine (2-CdA) in the treatment of relapsed and refractory chronic and lymphocytic leukemia. J Clin Oncol 1995: 13: 983-988.
18. KAY AC, SAVEN A, CARRERA CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade non Hodgkin's lymphoma. J Clin Oncol 1992: 10: 371-377.
19. HICKISH T, SERAFINOWSKI P, CUNNINGHAM D, et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selectove agent in lymphoid malignancies. Br J Cancer 1993: 67: 139-143.
20. HOFFMAN M, TALLMAN M, HAKIMIAN D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994: 12: 788-792.
21. SAVEN A, CARRERA CJ, CARSON DA, et al. 2-Chlorodeoxyadenosine an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992: 80: 587-592.
22. O'BRIEN S, KURZROCK R, DUVIC M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994: 84: 733-740.
23. KUZEL TM, SAMUELSON E, ROEGNICK H, et al. Phase II trial of 2-chlorodeoxyadenosine (2-CdA) for the treatment of mycosis fungoides or the Sezary syndrome (MF/SS). Proc Am Soc Clin Oncol 1992: 11: 1089 (abstr).
24. CHESON BD, BENNET JM, RAI KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia. Am J Hematol 1988: 29: 152-163.
25. TALLMAN S, HAKIMIAN D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995: 86: 2463-2474.
26. SAVEN A, LEMON RH, PIRO LD. 2-chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993: 328: 812 (letter).
27. O'BRIEN S, KANTARJIAN H, ESTEY E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994: 330: 319-322.
28. JULIUSSON G, ELMHORN-ROSENBERG A, LILIEMARK J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993: 327: 1056-1061.
29. LAURIA F, RONDELLI D, RASPADORI D, et al. Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy cell leukemia. Eur J Haematol 1994: 52: 16-20.